Aprea Therapeutics, Inc. Common stock (APRE)

Price$0.82

Growth ScoreF

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-35.52%

Price vs S&P 500 (4W)4.15%

VGM Score17.63

Market Capitalization$11.05M

All Metrics

Book Value / Share (Quarterly)$3.53

P/TBV (Annual)0.54x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.00

Price vs S&P 500 (YTD)-6.29%

Net Profit Margin (TTM)-4409.14%

EPS (TTM)$-1.54

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$-1.54

EPS (Annual)$-1.93

ROI (Annual)-95.68%

Cash / Share (Quarterly)$3.88

Revenue Growth QoQ (YoY)-98.38%

ROA (Last FY)-79.08%

Revenue Growth TTM (YoY)-90.40%

EBITD / Share (TTM)$-1.44

ROE (5Y Avg)-145.80%

Operating Margin (TTM)-4631.10%

Cash Flow / Share (Annual)$-1.57

P/B Ratio0.26x

P/B Ratio (Quarterly)0.21x

Net Income / Employee (Annual)$-1,574,900

EV / Revenue (TTM)-123.93x

Net Interest Coverage (TTM)-78.82x

ROA (TTM)-50.24%

EPS Incl Extra (Annual)$-1.93

Current Ratio (Annual)5.63x

Quick Ratio (Quarterly)8.77x

3-Month Avg Trading Volume1.68M

52-Week Price Return-50.55%

Revenue / Employee (TTM)$15,400

Tangible BV / Share (Quarterly)$5.78

P/S Ratio (Annual)38.68x

Asset Turnover (Annual)0.02x

52-Week High$2.22

EPS Excl Extra (Annual)$-1.93

CapEx CAGR (5Y)-12.39%

Tangible BV CAGR (5Y)5.67%

26-Week Price Return-19.59%

Quick Ratio (Annual)5.28x

13-Week Price Return1.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.92x

Enterprise Value$-35.41M

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-53.04%

Revenue / Employee (Annual)$35,700

Pretax Margin (Annual)-4409.14%

Cash / Share (Annual)$1.78

3-Month Return Std Dev95.49%

Net Income / Employee (TTM)$-1,494,400

ROE (Last FY)-95.68%

Net Interest Coverage (Annual)-23.37x

EPS Basic Excl Extra (Annual)$-1.93

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.54

ROI (TTM)-58.84%

P/S Ratio (TTM)38.68x

Revenue / Share (Annual)$0.04

Tangible BV / Share (Annual)$10.15

Price vs S&P 500 (52W)-78.75%

Year-to-Date Return4.64%

5-Day Price Return-6.04%

EPS Normalized (Annual)$-1.93

ROA (5Y Avg)-126.92%

Net Profit Margin (Annual)-4409.14%

Month-to-Date Return11.59%

Cash Flow / Share (TTM)$-3.97

EBITD / Share (Annual)$-2.02

Operating Margin (Annual)-4631.10%

ROI (5Y Avg)-145.80%

EPS Basic Excl Extra (TTM)$-1.54

P/TBV (Quarterly)0.67x

P/B Ratio (Annual)0.45x

Pretax Margin (TTM)-4409.14%

Book Value / Share (Annual)$1.61

Price vs S&P 500 (13W)-8.33%

Beta-1.33x

Revenue / Share (TTM)$0.01

ROE (TTM)-58.84%

52-Week Low$0.55

gGradeF

mGradeD

vgmGradeF

Show chart for

Earnings Surprise History

Q1 26-0.22est. -0.23

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.22

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
APREAprea Therapeutics, Inc. Common stock	—	F	D	$0.82
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology therapies based on synthetic lethality. Its lead program, ATRN-119, is a small-molecule ATR inhibitor in clinical development for solid tumors. The company is also advancing APR-1051, an oral WEE1 inhibitor that recently entered clinical trials.